OBJECTIVE: To compare the efficacy and safety of chloroquine phosphate and lopinavir/ritonavir in the treatment of patients with COVID-19

so as to provide reference for the clinical treatment. METHODS: Thirty confirmed COVID-19 discharged patients（ 19 males and 11 females

aged from 19 to 78 years） were collected from Huizhou Central People’s Hospital from Jan. to Feb. 2020. According to different treatment methods

patients were divided into the study group（ 15 patients

treated with chloroquine 0. 5 g

orally

twice a day） and the control group（ 15 patients

treated with lopinavir/ritonavir 0. 5 g

orally

twice a day）. The efficacy and adverse drug reactions of two groups were compared. RESULTS: The average body temperature of the patients in the study group returned to normal time was（ 2. 0 ± 0. 3） d and that in the control group was（ 3. 3 ± 0. 6） d

the difference was statistically significant（ P < 0. 05）. The average nucleic acid negative time of respiratory virus specimens in the study group was（ 3. 6 ± 0. 4） d after treatment

while that in the control group was（ 14. 0 ± 0. 7） d after treatment

with statistically significant difference（ P < 0. 05）. The incidence of adverse drug reactions was 6. 7%（ 1/15） in the study group and66. 7%（ 10/15） in the control group

the difference was statistically significant（ P < 0. 05）. CONCLUSIONS: The effect of chloroquine phosphate is superior to lopinavir/ritonavir in improving clinical symptoms and accelerating virus clearance in COVID-19 patients

with the lower incidence of adverse drug reactions.